title: Subcutaneous nadroparin calcium in the treatment of recent onset retinal vein occlusion: a pilot study.
abstract: OBJECTIVE
  Optimal management of retinal vein occlusion (RVO) is still a matter of debate. The purpose of this pilot study was to investigate whether nadroparin calcium may play some role in the treatment of recent onset (≤3 weeks' duration) RVO.
  
  
  METHODS
  Twenty-four RVO patients were treated with subcutaneous nadroparin calcium (200 I.U./kg/day) for 6 weeks. Best corrected visual acuity (BCVA) and macular thickness in the affected eye were measured at baseline, and after 3 and 6 months. Twenty-four RVO patients treated with oral pentoxifylline, matched for age, gender, RVO type, eye involvement, and BCVA at presentation, randomly selected from the RVO register, were used as controls.
  
  
  RESULTS
  Median BCVAs at baseline, month 3, and month 6 were 20/70 (range: 20/1,000-20/20), 20/40 (range: 20/100-20/20), and 20/30 (range: 20/200-20/20) in cases and 20/70 (range: 20/1,000-20/20), 20/60 (range: 20/320-20/25), and 20/60 (range: 20/500-20/20) in controls. Differences between groups were statistically significant at months 3 (P=0.025) and 6 (P=0.024). In the study group, the mean macular thickness was 510±207 μm at baseline, 384±198 μm after 3 months, and 313±170 μm after 6 months. Differences between baseline and months 3 and 6 were statistically significant (P=0.004 and P<0.001).
  
  
  CONCLUSIONS
  Results suggest that nadroparin calcium might become a potential candidate for the treatment of RVO. Larger trials are necessary to confirm these preliminary findings.
authors.affiliation: Section of Ophthalmology, Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, Italy. apinna@uniss.it
authors.forename: Antonio
authors.initials: A
authors.lastname: Pinna
authors.forename: Piera
authors.initials: P
authors.lastname: Simula
authors.forename: Angelo
authors.initials: A
authors.lastname: Zinellu
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003627:Data Interpretation, Statistical; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D053685:Laser Therapy; D008266:Macula Lutea / Q000187:drug effects / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017762:Nadroparin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010865:Pilot Projects; D012170:Retinal Vein Occlusion / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D000925:Anticoagulants; D017762:Nadroparin